celltrace calcein red-orange dye (Thermo Fisher)
Thermo Fisher is a verified supplier 
Thermo Fisher manufactures this product 
90
Structured Review
Thermo Fisher
celltrace calcein red-orange dye
Celltrace Calcein Red Orange Dye, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/celltrace+calcein+red-orange+dye/pmc08203293-369-18-22
Average 90 stars, based on 1 article reviews
Celltrace Calcein Red Orange Dye, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/celltrace+calcein+red-orange+dye/pmc08203293-369-18-22
Average 90 stars, based on 1 article reviews
celltrace calcein red-orange dye - by Bioz Stars,
2026-09
90/100 stars
Images
1) Product Images from "Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment"
Article Title: Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment
Journal: eLife
doi: 10.7554/eLife.58688
Figure Legend Snippet: Migration of activated PBT plated onto fresh tumor slices was analyzed in EGI-1 and MMTV-PyMT tumor model, whilst resident tumor-infiltrating T lymphocytes were analyzed in mPDAC and KPC tumor model. Illustrative images of T cell migration tracks in EGI-1, MMTV-PyMT, mPDAC, and KPC tumor models. Tumor stroma (fibronectin) in red, tumor cells (EpCAM in EGI-1, MMTV-PyMT, and KPC tumor models, CD44 in mPDAC tumor models), in blue and T cells (CD8 in mPDAC and KPC, Calcein in MMTV-PyMT, and EGI-1 tumor models) in green. Tracks are color-coded to illustrate track displacement. Scale bar = 100 µm. T cell migration speed, T cell displacement, and trajectory straightness in all tumor models. ***p - value>0.001, p-value>0.05, Student’s t-test. Results are shown as mean ± SD. Figure 5—source data 1. Source data file for .
Techniques Used: Migration
Figure Legend Snippet:
Techniques Used: Derivative Assay, Recombinant, Cell Isolation, Activation Assay, Software
Related Articles
Migration:Article Title: Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment Article Snippet: To evaluate T cell migration in the EGI-1 model, activated human CD8+ T cells were first labeled with Article Title: Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment Article Snippet: To evaluate T cell migration in the EGI-1 model, activated human CD8+ T cells were first labeled with Labeling:Article Title: Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment Article Snippet: To evaluate T cell migration in the EGI-1 model, activated human CD8+ T cells were first labeled with Article Title: Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment Article Snippet: To evaluate T cell migration in the EGI-1 model, activated human CD8+ T cells were first labeled with Derivative Assay:Article Title: Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment Article Snippet: To evaluate T cell migration in the EGI-1 model, activated human CD8+ T cells were first labeled with Article Title: Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment Article Snippet: To evaluate T cell migration in the EGI-1 model, activated human CD8+ T cells were first labeled with Recombinant:Article Title: Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment Article Snippet: To evaluate T cell migration in the EGI-1 model, activated human CD8+ T cells were first labeled with Article Title: Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment Article Snippet: To evaluate T cell migration in the EGI-1 model, activated human CD8+ T cells were first labeled with Cell Isolation:Article Title: Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment Article Snippet: To evaluate T cell migration in the EGI-1 model, activated human CD8+ T cells were first labeled with Article Title: Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment Article Snippet: To evaluate T cell migration in the EGI-1 model, activated human CD8+ T cells were first labeled with Activation Assay:Article Title: Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment Article Snippet: To evaluate T cell migration in the EGI-1 model, activated human CD8+ T cells were first labeled with Article Title: Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment Article Snippet: To evaluate T cell migration in the EGI-1 model, activated human CD8+ T cells were first labeled with Software:Article Title: Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment Article Snippet: To evaluate T cell migration in the EGI-1 model, activated human CD8+ T cells were first labeled with Article Title: Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment Article Snippet: To evaluate T cell migration in the EGI-1 model, activated human CD8+ T cells were first labeled with |